Publication | Closed Access

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

MedicineMelanomaClinical TrialsImmune Checkpoint InhibitorDermatologyCancer Treatment4-Year OutcomesOncologyAdvanced MelanomaCheckmate 067